Australian researchers have uncovered yet another link between the controversial Paleolithic diet and heart disease.

The FDA on July 15 approved Sun Pharmaceutical Industries’ sprinkle formulation of rosuvastatin, an alternative to traditional lipid-lowerers for patients who have difficulty swallowing.

Toward the end of June, around a dozen American diabetics took an 817-mile caravan ride from Minneapolis to London, Ontario, in an effort to obtain more affordable insulin, CBS News reports. It was the second caravan in two months to make the trip.

Abbott Laboratories is planning to increase production of its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the coming years, Reuters reported July 16.

A study published in the New England Journal of Medicine July 18 suggests it may be time for the medical community to rethink its perception of diastolic blood pressure, which has long been considered inferior to systolic BP as a measure of cardiovascular wellness.

Massachusetts-based Azurity Pharmaceuticals announced July 10 it had received FDA approval for Katerzia Oral Suspension, making the drug the first and only FDA-approved amlodipine oral suspension to hit the commercial market.

Multivitamins and the bulk of nutritional supplements do little to protect heart health, in some cases increasing a person’s risk for CV events, an analysis published in the Annals of Internal Medicine has found.

Research published in Hypertension July 1 suggests a vitamin D deficiency in early childhood could translate to an increased risk of high blood pressure in adolescence.